0000000000286033

AUTHOR

Hans-jochen Decker

showing 6 related works from this author

The von Hippel-Lindau tumor suppressor gene

1997

Abstract The von Hippel-Lindau (VHL) disease is an inherited tumor susceptibility syndrome featuring a high variety of benign and malignant tumors. The gene has been localized and cloned at 3p25-26. Recent functional analysis defined the VHL gene product as an inhibitor of the transcription elongation process. Its possible involvement in the vascularization process may explain the histologic features of VHL tumors providing insight into basic mechanism of tumorigenesis. Direct genetic testing is available for patients affected with VHL. Seventy to eighty percent of the germline mutations expected could be detected. As first geno/phenotype correlations have been established, we are now begin…

GeneticsCancer Researchendocrine system diseasesmedicine.diagnostic_testTumor suppressor geneBiologyurologic and male genital diseasesmedicine.diseasemedicine.disease_causePhenotypefemale genital diseases and pregnancy complicationsGermline mutationVon Hippel–Lindau tumor suppressorGeneticsmedicineCancer researchbiology.proteinVon Hippel–Lindau diseaseCarcinogenesisMolecular BiologyGeneGenetic testingCancer Genetics and Cytogenetics
researchProduct

Autologous Transplantation of In Vivo Purged PBSC in CML

2000

To determine the effectiveness of different methods for the detection of tumor cell contamination of collected peripheral stem cells, we performed a study on 39 chronic myelogenous leukemia (CML) patients who were consecutively treated at our department. Analyses of tumor cell contamination by fluorescence in situ hybridization (FISH), conventional cytogenetics, and polymerase chain reaction (PCR) showed marked differences in the percentage of evaluable results: Quantitative analysis of tumor cell contamination was feasible in 60 of 105 (57%) samples evaluated with the use of conventional cytogenetic analysis and in 105 of 107 (98%) samples analyzed by FISH. PCR was evaluable in all 85 samp…

OncologyCancer Researchmedicine.medical_specialtymedicine.diagnostic_testCytogeneticsLeukapheresisBiologymedicine.diseasePhiladelphia chromosomelaw.inventionlawInternal medicineImmunologyGeneticsmedicineAutologous transplantationStem cellMolecular BiologyPolymerase chain reactionChronic myelogenous leukemiaFluorescence in situ hybridizationCancer Genetics and Cytogenetics
researchProduct

Tracheal development and the von Hippel-Lindau tumor suppressor homolog in Drosophila.

2000

von Hippel-Lindau disease is a hereditary cancer syndrome. Mutations in the VHL tumor suppressor gene predispose individuals to highly vascularized tumors. However, VHL-deficient mice die in utero due to a lack of vascularization in the placenta. To resolve the contradiction, we cloned the Drosophila VHL homologue (d-VHL) and studied its function. It showed an overall 50% similarity to the human counterpart and 76% similarity in the crucial functional domain: the elongin C binding site. The putative d-VHL protein can bind Drosophila elongin C in vitro. During embryogenesis, d-VHL is expressed in the developing tracheal regions where tube outgrowth no longer occurs. Reduced d-VHL activity (u…

Cancer Researchendocrine system diseasesTumor suppressor geneUbiquitin-Protein LigasesMolecular Sequence Dataurologic and male genital diseasesTube fusionLigasesRNA interferenceVon Hippel–Lindau tumor suppressorGeneticsmedicineAnimalsHumansGenes Tumor SuppressorAmino Acid SequenceVon Hippel–Lindau diseaseCloning MolecularneoplasmsMolecular BiologyGeneticsbiologyTumor Suppressor ProteinsProteinsCell migrationEmbryomedicine.diseasePhenotypefemale genital diseases and pregnancy complicationsCell biologyTracheaPhenotypeVon Hippel-Lindau Tumor Suppressor Proteinbiology.proteinDrosophilaOncogene
researchProduct

Detection of a germline mutation and somatic homozygous loss of the von Hippel-Lindau tumor-suppressor gene in a family with a de novo mutation

1996

von Hippel-Lindau (VHL) disease is a pleiotropic disorder featuring a variety of malignant and benign tumors of the eye, central nervous system, kidney, and adrenal gland. Recently the VHL gene has been identified in the chromosomal region 3p25-26. Prognosis and successful management of VHL patients and their descendants depend on unambiguous diagnosis. Due to recurrent hemangioblastomas, a29-year-old patient without familial history of VHL disease was diagnosed to be at risk for the disease. Histopathological examination of a small renal mass identified a clear cell tumor with a G1 grading. Genetic characterization of the germline and of the renal tumor was performed. Polymerase chain reac…

AdultMalemedicine.medical_specialtyvon Hippel-Lindau DiseaseTumor suppressor geneDNA Mutational AnalysisMolecular Sequence Dataurologic and male genital diseasesPolymerase Chain ReactionGermlineGermline mutationVon Hippel–Lindau tumor suppressorGeneticsmedicineHumansGenes Tumor SuppressorSpinal Cord NeoplasmsVon Hippel–Lindau diseaseGerm-Line MutationPolymorphism Single-Stranded ConformationalGenetics (clinical)Sequence Deletionbiologymedicine.diagnostic_testHomozygoteCytogeneticsExonsmedicine.diseaseKidney Neoplasmsfemale genital diseases and pregnancy complicationsHemangioblastomaPedigreeKaryotypingChromosomal regionbiology.proteinCancer researchFemaleChromosomes Human Pair 3Chromosome DeletionFluorescence in situ hybridizationHuman Genetics
researchProduct

Complete karyotype characterization of the K562 cell line by combined application of G-banding, multiplex-fluorescence in situ hybridization, fluores…

2001

This study combines conventional cytogenetics, fluorescence in situ hybridization (FISH), multiplex-FISH and comparative genomic hybridization (CGH). In applying this multimodal approach on the human leukemia cell line K562, the chromosome composition was refined in detail and compared with data from the literature. A hypotriploid karyotype with a modal chromosome number of 67, and 21 unique marker chromosomes were identified. The classification of six markers was identical to published data and the composition of five further markers from the literature could be fully clarified for the first time. The composition of another five markers, which have been interpreted in divergent ways in dif…

Genetic MarkersCancer Researchmedicine.medical_specialtyG bandingIn situ hybridizationComputational biologyBiologyChromosome PaintingCytogeneticsmedicineHumansIn Situ Hybridization FluorescenceGeneticsmedicine.diagnostic_testCytogeneticsChromosome MappingNucleic Acid HybridizationKaryotypeHematologyModal Chromosome NumberOncologyKaryotypingK562 CellsVirtual karyotypeComparative genomic hybridizationFluorescence in situ hybridizationLeukemia research
researchProduct

Genesis of variant Philadelphia chromosome translocations in chronic myelocytic leukemia.

2003

The Philadelphia (Ph) chromosome is found in more than 90% of chronic myelocytic leukemia (CML) patients. In most cases, it results from the reciprocal t(9;22)(q34;q11), with the ABL proto-oncogene from 9q34 fused to the breakpoint cluster region (BCR) locus on 22q11. In 5%-10% of patients with CML, the Ph chromosome originates from variant translocations, involving various breakpoints in addition to 9q34 and 22q11. In our investigation, three CML cases with complex Ph translocations have been analyzed by G-banding and fluorescence in situ hybridization (FISH). FISH with breakpoint-spanning probes for the BCR and ABL genes revealed information about the genesis of complex Ph translocations.…

AdultGenetic MarkersMaleCancer Researchmedicine.medical_specialtyChromosomes Human Pair 22Chromosomal translocationLocus (genetics)BiologyPhiladelphia chromosomeProto-Oncogene MasTranslocation Genetichemic and lymphatic diseasesLeukemia Myelogenous Chronic BCR-ABL PositiveGeneticsmedicineHumansPhiladelphia ChromosomeMolecular BiologyIn Situ Hybridization FluorescenceGeneticsABLmedicine.diagnostic_testChromosomes Human Pair 11BreakpointCytogeneticsbreakpoint cluster regionGenetic VariationMiddle Agedmedicine.diseaseChromosome BandingKaryotypingFemaleChromosomes Human Pair 9Fluorescence in situ hybridizationCancer genetics and cytogenetics
researchProduct